UK fraud office launches probe into GSK
Print Edition
BRITAIN’S fraud office has launched a formal criminal investigation into GlaxoSmithKline, posing a new challenge to the drugmaker, which already faces claims of bribery in China and four other countries.
The Serious Fraud Office said its director had “opened a criminal investigation into the commercial practices of GlaxoSmithKline and its subsidiaries,” confirming an earlier brief statement from the company.
“GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO,” the company said.
Neither the SFO nor GSK gave any further details about the case, and a company spokesman declined to elaborate. However, one person familiar with the matter said the SFO was investigating GSK’s practices in “numerous” jurisdictions.
The SFO action comes less than two weeks after Chinese police said they had charged the former British boss of GSK’s China business and other colleagues with corruption, after an investigation there found evidence of an elaborate scheme to bribe doctors and hospitals.
The case is the biggest corruption scandal to hit a foreign company in China since the Rio Tinto affair in 2009, which saw four executives, including an Australian, being jailed.
The decision by the SFO does not come as a complete surprise, since lawyers and industry analysts had said that allegations against GSK — Britain’s biggest drugmaker and the sixth-largest pharmaceuticals group in the world by sales — in overseas markets could expose it to charges under the UK Bribery Act.
The new act, like the long-established US Foreign Corrupt Practices Act, bars payments to government officials, including state-employed doctors, to obtain business overseas.
However, GSK can claim mitigation against prosecution if it can show that it had robust policies and procedures in place that were circumvented by rogue employees.
“Given GSK is UK headquartered it perhaps isn’t very surprising to hear that the SFO is looking at the issue too and that they may be interested in activities since July 1, 2011, when the Bribery Act came into force, as from that date the corporate offense of failing to prevent bribery began to apply,” said Omar Qureshi, a partner at law firm CMS Cameron McKenna.
US authorities are already investigating the British drugmaker for possible violations of US anti-bribery laws in China, sources familiar with the matter said last September.
Societe Generale analyst Stephen McGarry said the ability to claim mitigating circumstances meant GSK might not face major fines, but the bad publicity “may restrain GSK’s share price performance in the near-term.”
Authorities in China first accused GSK last July of funneling up to 3 billion yuan (US$481 million) in bribes to encourage doctors to use its medicines in a case that the company described in 2013 as “shameful.”
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
